Publicaciones (52) Publicaciones de Ignacio Matos García

2024

  1. Fcγ receptors and immunomodulatory antibodies in cancer

    Nature Reviews Cancer, Vol. 24, Núm. 1, pp. 51-71

  2. Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis

    British Journal of Surgery, Vol. 111, Núm. 2

  3. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

    Nature Cancer

2023

  1. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

    Nature, Vol. 616, Núm. 7957, pp. 563-573

  2. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  3. Druggable Targets in Cytokine Release Syndromes

    Clinical Cancer Research, Vol. 29, Núm. 21, pp. 4320-4322

  4. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

    Nature Medicine

  5. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

    Clinical Cancer Research, Vol. 29, Núm. 12, pp. 2250-2265

  6. Genomic–transcriptomic evolution in lung cancer and metastasis

    Nature, Vol. 616, Núm. 7957, pp. 543-552

  7. Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials

    The oncologist, Vol. 28, Núm. 4, pp. e205-e211

  8. Lung adenocarcinoma promotion by air pollutants

    Nature, Vol. 616, Núm. 7955, pp. 159-167

  9. The evolution of lung cancer and impact of subclonal selection in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 525-533

  10. The evolution of non-small cell lung cancer metastases in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 534-542

  11. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

    Nature, Vol. 616, Núm. 7957, pp. 553-562

2022

  1. A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer

    Nature Cancer, Vol. 3, Núm. 6, pp. 696-709

  2. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling

    Nature Cancer, Vol. 3, Núm. 11, pp. 1336-1350

  3. Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)

    Nature Cancer

  4. Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447] (ESMO Open (2022) 7(2), (S2059702922000631), (10.1016/j.esmoop.2022.100447))

    ESMO Open

  5. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

    ESMO Open, Vol. 7, Núm. 2

2021

  1. A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors

    Radiology, Vol. 299, Núm. 1, pp. 109-119